5 More Monster Stocks To Watch For The Week of September 30

Tesla (TSLAWealth Strength IndexAAPL is Extremely Up and trending Up)

How can Tesla not be one of the stock to watch. The company will be releasing its third quarter delivery and production numbers by no later than October 3. A “leaked” email revealed the company was close to 100,000 deliveries in the third quarter.

If the stock can ever manage to get beyond this resistance zone between 253 to 260, it would open the door for the share to return $300.

tesla, tsla

tesla, tsla

Apple (AAPLWealth Strength IndexAAPL is Extremely Up and trending Up)

Apple has this descending triangle that is forming. It could mean that shares are due to fall to around $209.

apple, aapl

apple, aapl

Netflix (NFLXWealth Strength IndexAAPL is Extremely Up and trending Up)

Netflix has this flag pattern that has formed on the intraday chart, and at the very least, it suggests that shares challenge resistance at $273.

netflix, nflx

netflix, nflx

Roku (ROKU)

I don’t think Roku is finished falling, not yet. Perhaps this week it will test support $92.

roku

roku

Regeneron (REGNWealth Strength IndexAAPL is Extremely Up and trending Up)

Regeneron is one of those biotech stocks that are getting slammed. The stock is fighting on to hold support in the $270 to $280 range. The next significant level to watch is around $218. That declining relative strength index suggests the stock continues to fall.

regn

regn

That is going to all have a great Sunday!

-Mike

Source: Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.